Growth hormone

Tesamorelin

Egrifta

Tesamorelin is a growth hormone-releasing factor analog approved by the FDA as Egrifta for a narrow use: reducing excess abdominal fat in people with HIV-associated lipodystrophy. Uses outside that label have not been established by FDA review.

Key facts

  • Commonly discussed for: reducing belly (visceral) fat.
  • Evidence (B): Two phase 3 placebo-controlled trials (412 and 404 patients with HIV) showed visceral fat reductions of about 15% and 11% versus placebo over 26 weeks. Evidence for other uses is limited, so it is graded for a narrow approved indication.
  • FDA status: FDA-approved. FDA approved Egrifta in November 2010 for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
  • Legitimate access: Rx brand.
  • Last reviewed: October 1, 2026.

Common questions

Is tesamorelin FDA approved?

Yes. FDA approved tesamorelin as Egrifta in November 2010 for one use: reducing excess abdominal (visceral) fat in adults with HIV-associated lipodystrophy. Any other use is off-label.

Is tesamorelin approved for fat loss in people without HIV?

No. The approval covers HIV-associated lipodystrophy only. Using it for general fat loss, body composition or anti-aging has not been reviewed or approved by FDA.

How do people get tesamorelin legally?

With a prescription from a licensed provider for the brand product, Egrifta. A prescriber can decide to use an approved drug off-label, but that is a medical decision, not an FDA-approved use.

Sources